|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61P 35/00 | (2006.01) | ||
| C07K 16/24 | (2006.01) | ||
| A61K 39/395 | (2006.01) |
| (11) | Number of the document | 3328425 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16750495.0 |
| Date of filing the European patent application | 2016-07-27 | |
| (97) | Date of publication of the European application | 2018-06-06 |
| (45) | Date of publication and mention of the grant of the patent | 2021-08-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2016/054487 |
| Date | 2016-07-27 |
| (87) | Number | WO 2017/017623 |
| Date | 2017-02-02 |
| (30) | Number | Date | Country code |
| 201562198384 P | 2015-07-29 | US | |
| 201662352637 P | 2016-06-21 | US |
| (72) |
FJAELLSKOG, Marie-Louise , US
CAMERON, John , US
CAO, Zhu , US
CIPOLLETTA, Daniela , US
MACISAAC, Kenzie , US
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER |
| COMBINED USE OF ANTI PD-1 AND ANTI M-CSF ANTIBODIES IN THE TREATMENT OF CANCER |